oncnursingnews3h
Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
oncnursingnews4d
Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer
Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...
oncnursingnews4d
FDA Fast Tracks ALE.P02 for CLDN1-Poisitive Solid Cancers
The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...
oncnursingnews2d
FDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPC
The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...
oncnursingnews2d
Sabrina Mikan, PhD, RN, ACNS-BC
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews2d
Sharon Kauffman, PhD, RN, CNE, NPD-BC, OCN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
Eric Blackstone, MA, Sara L. Douglas, PhD, RN, Amy R. Lipson, PhD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5d
Patricia Kropf, MD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews6d
Bispecific Antibodies Are ‘Not Your Typical Chemotherapy’ in Myeloma Treatment
While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...